Goserelin
- Generic Name
- Goserelin
- Brand Names
- Zoladex
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N18O14
- CAS Number
- 65807-02-5
- Unique Ingredient Identifier
- 0F65R8P09N
- Background
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
- Indication
Goserelin is indicated for:
- Associated Conditions
- Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
- Associated Therapies
- Palliative Treatment
Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
- Conditions
- Age-related Wet Macular Degeneration
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Caregen Co. Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT06132035
- Locations
- 🇺🇸
CBCC Global Research Site:005, Manchester, Connecticut, United States
🇺🇸CBCC Global Research Site:006, Deerfield Beach, Florida, United States
🇺🇸CBCC Global Research Site:007, Philadelphia, Pennsylvania, United States
Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)
- Conditions
- Ewing SarcomaSynovial SarcomaRhabdomyosarcoma
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 30
- Registration Number
- NCT06094101
- Locations
- 🇩🇪
Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum, Freiburg, Germany
🇩🇪Universitätsklinikum, Klinik für Kinder- und Jugendmedizin, Frankfurt am Main, Germany
🇩🇪Pediatrics III, West German Cancer Centre, University Hospital, Essen, Germany
A Study to Assess the Safety, Tolerability and Preliminary Efficacy of HH-120 for the Treatment of COVID-19
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Huahui Health
- Target Recruit Count
- 37
- Registration Number
- NCT06039163
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
🇨🇳Beijing Ditan Hospital,Capital Medical University, Beijing, Beijing, China
🇨🇳Guangzhou Eighth People's,Guangzhou Medical University, Guangzhou, Guangdong, China
To Prevent Type I-II Myoma After TCRM Recurrence by Gonadotropin-releasing Hormone (GnRH )Analogues or Mifepristone
- Conditions
- Submucous Leiomyoma of Uterus
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2023-06-12
- Target Recruit Count
- 294
- Registration Number
- NCT05898321
- Locations
- 🇨🇳
Women's Hospital School of Medicine Zhejiang University, Hangzhou, Zhejiang, China
LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery
- Conditions
- Acute Kidney InjuryCardiac Surgery
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Arch Biopartners Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT05879432
- Locations
- 🇨🇦
Cumming School of Medicine & Libin Cardiovascular Centre, University of Calgary, Calgary, Alberta, Canada
🇨🇦Unity Health Toronto, St. Michael's Hospital, Toronto, Ontario, Canada
🇨🇦University Health Network, Toronto, Ontario, Canada
Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05856630
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
- Conditions
- Stage 0is Bladder Cancer AJCC v8High Risk Non-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 30
- Registration Number
- NCT05843448
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Conditions
- Early Breast Cancer
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1400
- Registration Number
- NCT05827081
- Locations
- 🇺🇸
Ocala Research Institute, Inc, Ocala, Florida, United States
🇺🇸Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
🇺🇸Washington Hospital Center, Washington, District of Columbia, United States
Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia
- Conditions
- Neoadjuvant Endocrine TherapyBreast Cancer
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 300
- Registration Number
- NCT05800197
- Locations
- 🇷🇺
Blokhin's Russian Cancer Research Center, Moscow, Russian Federation
HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Huahui Health
- Target Recruit Count
- 1200
- Registration Number
- NCT05787418
- Locations
- 🇨🇳
Beijing Ditan Hospital, Capital Medical University, Beijing, China
🇨🇳Huashan Hospital of Fudan University, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.